94
Participants
Start Date
November 8, 2022
Primary Completion Date
January 6, 2024
Study Completion Date
May 16, 2024
Deucravacitinib
Specified dose on specified days
Placebo
Placebo was administered.
Local Institution - 0003, Kogarah
Local Institution - 0005, Carlton
Local Institution - 0020, Paris
Local Institution - 0012, Austin
Local Institution - 0017, South Jordan
Local Institution - 0016, Santa Monica
Local Institution - 0036, New Haven
Local Institution - 0018, Tampa
Local Institution - 0023, Clinton Township
Local Institution - 0024, New York
Local Institution - 0019, Chapel Hill
Local Institution - 0011, Portland
Local Institution - 0032, Pittsburgh
Local Institution - 0013, Houston
Local Institution - 0014, San Antonio
Local Institution - 0015, Winnipeg
Local Institution - 0021, Markham
Local Institution - 0009, Peterborough
Local Institution - 0010, Richmond Hill
Local Institution - 0034, Montreal
Local Institution - 0027, Québec
Local Institution - 0033, Nice
Local Institution - 0031, Hamamatsu
Local Institution - 0028, Kōtoku
Local Institution - 0030, Mitaka-Shi
Local Institution - 0029, Shinjuku-Ku
Local Institution - 0026, Wroclaw
Local Institution - 0025, Warsaw
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY